City Therapeutics appoints Andrew Orth as CEO, leveraging his expertise in RNA and gene therapies as the company advances its ...

I-Mab shifts focus to givastomig, a bispecific antibody for CLDN18.2-positive tumors, following positive early data and ...

Denali Therapeutics' DNL343 fails to meet endpoints in the HEALEY ALS study, marking a second clinical setback for the ...

Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space. How has ...

The US Food and Drug Administration (FDA) issued a draft guidance to provide recommendations on the use of artificial ...

Sentynl Therapeutics secures FDA priority review for CUTX-101, a potential first treatment for Menkes disease. Supported by ...

Administration (FDA) approved an update to the US Prescribing Information (USPI) for Pyrukynd (mitapivat) for the treatment ...

Chinese researchers use AI to identify HG9-91-01, a potential neuroprotective treatment for glaucoma. The molecule shows ...

Taiwan-based GlycoNex, a biotech company focused on the development of glycan-directed cancer immunotherapies, has announced a licensing agreement for its denosumab biosimilar, SPD8.

Patrick Branch, head of Japan and APAC business development at Nxera Pharma, Japan’s most innovative and nimble biopharma ...

Immedica Pharma acquires Marinus Pharmaceuticals for $151 million, gaining the rare disease treatment Ztalmy and expanding ...

China’s National Medical Products Administration (NMPA) has approved Astellas Pharma’s Vyloy (zolbetuximab), in combination ...